MabCampath 30mg/ml concentrate for solution for infusion (2012)
Βιβλιογραφική αναφορά
Στοιχεία εκδότη
| Εκδότης | Genzyme Therapeutics |
|---|---|
| Διεύθυνση | 4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, Oxfordshire, OX4 2SU |
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Name of the medicinal product
MabCampath 30 mg/ml concentrate for solution for infusion.
Qualitative and quantitative composition
One ml contains 30 mg of alemtuzumab. Each vial contains 30 mg of alemtuzumab. Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface ...
Pharmaceutical form
Concentrate for solution for infusion. Colourless to slightly yellow concentrate.
Therapeutic indications
MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.
Posology and method of administration
MabCampath should be administered under the supervision of a physician experienced in the use of cancer therapy. Posology During the first week of treatment, MabCampath should be administered in escalating ...
Contraindications
Hypersensitivity to alemtuzumab, to murine proteins or to any of the excipients. Active systemic infections. HIV. Active second malignancies. Pregnancy.
Special warnings and precautions for use
Acute adverse reactions, which may occur during initial dose escalation and some of which may be due to the release of cytokines, include hypotension, chills/rigors, fever, shortness of breath and rashes. ...
Interaction with other medicinal products and other forms of interaction
Although no formal drug interaction studies have been performed with MabCampath, there are no known clinically significant interactions of MabCampath with other medicinal products. Because MabCampath is ...
Pregnancy and lactation
Pregnancy MabCampath is contraindicated during pregnancy. Human IgG is known to cross the placental barrier; MabCampath may cross the placental barrier as well and thus potentially cause foetal B and T ...
Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. However, caution should be exercised as confusion and somnolence have been reported.
Undesirable effects
The tables below report adverse reactions by MedDRA system organ classes (MedDRA SOCs). The frequencies are based on clinical trial data. The most appropriate MedDRA term is used to describe a certain ...
Overdose
Patients have received repeated unit doses of up to 240 mg of MabCampath. The frequency of grade 3 or 4 adverse events, such as fever, hypotension and anaemia, may be higher in these patients. There is ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies ATC code: L01XC04 Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte ...
Pharmacokinetic properties
Pharmacokinetics were characterised in MabCampath-naive patients with B-cell chronic lymphocytic leukaemia (B-CLL) who had failed previous therapy with purine analogues. MabCampath was administered as ...
Preclinical safety data
Preclinical evaluation of alemtuzumab in animals has been limited to the cynomolgus monkey because of the lack of expression of the CD52 antigen on non-primate species. Lymphocytopenia was the most common ...
List of excipients
Disodium edetate Polysorbate 80 Potassium chloride Potassium dihydrogen phosphate Sodium chloride Dibasic sodium phosphate Water for injections
Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. There are no known incompatibilities with other medicinal products. However, other medicinal ...
Shelf life
Unopen vial: 3 years. Reconstituted solution: MabCampath contains no antimicrobial preservative. MabCampath should be used within 8 hours after dilution. Solutions may be stored at 15°C-30°C or refrigerated. ...
Special precautions for storage
Store in a refrigerator (2°C-8°C). Do not freeze. Store in the original package in order to protect from light. For storage conditions of the reconstituted medicinal product, see section 6.3.
Nature and contents of container
Clear type I glass vial, closed with a rubber stopper, containing 1 ml of concentrate. Pack size: carton of 3 vials.
Special precautions for disposal and other handling
The vial contents should be inspected for particulate matter and discolouration prior to administration. If particulate matter is present or the concentrate is coloured, then the vial should not be used. ...
Marketing authorization holder
Genzyme Europe BV Gooimeer 10 1411 DD Naarden Netherlands
Marketing authorization number(s)
EU/1/01/193/002
Date of first authorization / renewal of the authorization
Date of first authorisation: 06/07/2001 Date of latest renewal: 10/07/2011
Date of revision of the text
05/2011